TAK-779

TAK-779 is a potent, non-peptide small molecule antagonist of the chemokine receptors CCR5 and CXCR3. Developed by Takeda Pharmaceutical Company, it was the first non-peptide CCR5 antagonist to enter clinical development, primarily investigated for its ability to inhibit HIV-1 entry by blocking the interaction between the viral envelope protein gp120 and the CCR5 co-receptor. Although clinical development for HIV was discontinued due to poor oral bioavailability and unfavorable pharmacological properties (requiring subcutaneous administration), TAK-779 remains a widely used research tool. It is frequently employed in preclinical models of inflammatory diseases, autoimmune disorders, and oncology to investigate the roles of CCL5/CCR5 and CXCL10/CXCR3 signaling axes in leukocyte trafficking and the modulation of the tumor microenvironment, particularly in reducing regulatory T cell (Treg) recruitment.